Bristol-Myers Squibb Company (BMY) Business News

Track Bristol-Myers Squibb Company in real time with a live news feed covering Bristol-Myers Squibb Company stock news, official press releases, company announcements, and an archive of historical Bristol-Myers Squibb Company news. ...more

  • Calendar
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
11:21 AM | Tuesday | Oct 13, 2026 Business Insider

FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban

News Thumbnail
12:51 PM | Monday | Oct 12, 2026 Zacks Investment Research

BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?

News Thumbnail
11:14 AM | Monday | Oct 12, 2026 GuruFocus

Bristol Myers Squibb (BMY) Gains on Positive Phase 3 Results for RYZ101 and Admilparant

News Thumbnail
6:55 AM | Monday | Oct 12, 2026 Business Wire

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs

News Thumbnail
6:50 AM | Monday | Oct 12, 2026 Business Wire

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

News Thumbnail
12:13 PM | Saturday | Oct 10, 2026 Fool - Investing News

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

News Thumbnail
3:05 AM | Saturday | Oct 10, 2026 Defense World

20,370 Bristol Myers Squibb Company $BMY Shares Bought by Apella Capital LLC

News Thumbnail
12:27 PM | Thursday | Oct 8, 2026 Benzinga

Bristol Myers Squibb's Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%

News Thumbnail
6:59 AM | Thursday | Oct 8, 2026 Business Wire

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs.

News Thumbnail
10:40 AM | Wednesday | Oct 7, 2026 Zacks Investment Research

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

News Thumbnail
news photo
Loading...

The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.

Read full article redirect
11:21 AM | Tuesday | Oct 13, 2026

FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban

Business Insider

The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.

Read full article arrow
News Thumbnail
12:51 PM | Monday | Oct 12, 2026

BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?

Zacks Investment Research

Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.

Read full article arrow
News Thumbnail
11:14 AM | Monday | Oct 12, 2026

Bristol Myers Squibb (BMY) Gains on Positive Phase 3 Results for RYZ101 and Admilparant

GuruFocus

Bristol Myers Squibb (BMY) shares are rising following encouraging Phase 3 results for RYZ101 and admilparant, which present two promising growth avenues as the

Read full article arrow
News Thumbnail
6:55 AM | Monday | Oct 12, 2026

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACTION--BMS Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101.

Read full article arrow
News Thumbnail
6:50 AM | Monday | Oct 12, 2026

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ALOFT--Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint.

Read full article arrow
News Thumbnail
12:13 PM | Saturday | Oct 10, 2026

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Fool - Investing News

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.

Read full article arrow
News Thumbnail
3:05 AM | Saturday | Oct 10, 2026

20,370 Bristol Myers Squibb Company $BMY Shares Bought by Apella Capital LLC

Defense World

Apella Capital LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 159.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,162 shares of the biopharmaceutical company's stock after purchasing an additional 20,370 shares during

Read full article arrow
News Thumbnail
12:27 PM | Thursday | Oct 8, 2026

Bristol Myers Squibb's Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%

Benzinga

Bristol Myers Squibb & Co. (NYSE:BMY) announced topline results from its Phase 3 EXCALIBER-RRMM study on Thursday.

Read full article arrow
News Thumbnail
6:59 AM | Thursday | Oct 8, 2026

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs.

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Myeloma--Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior.

Read full article arrow
News Thumbnail
10:40 AM | Wednesday | Oct 7, 2026

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

Zacks Investment Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read full article arrow
News Thumbnail